🚨 A new KRAS G12C winner at #ESMO26?
KRASCENDO-1 (Phase III): Divarasib vs sotorasib/adagrasib in previously treated NSCLC.
🔥 PFS: 9.8 vs 5.7 months (HR 0.58)
🔥 OS: 17.7 vs 12.0 months (HR 0.56)
🔥 ORR: 58% vs 32%
Even fewer Grade ≥3 TRAEs!
A potential new standard for KRAS G12C NSCLC.
@my_esmo @ESMO_open @ASCO @oncoalert #LungCancer
121 views · 1 like · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10 Trials 1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC 2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC 3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors 4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC 5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression 6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel 7.SARON | Consolidation RT in oligometastatic NSCLC 8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50% 9.DeLLphi-304 | Long-term survival with tarlatamab 10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1. Which trial could have the biggest impact on lung cancer treatment? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #LungCancer #Oncology在 X 查看被引用的帖子
Source: Dr Rishabh Jain · x.com